Literature DB >> 15886013

Arginine deprivation and metabolomics: important aspects of intermediary metabolism in relation to the differential sensitivity of normal and tumour cells.

Denys N Wheatley1.   

Abstract

Arginine deprivation causes many types of tumour cells to die, often because they cannot recover or convert urea cycle intermediates into arginine. The powerful homeostatic mechanisms that kicks in to restore arginine levels in vivo are lacking in vitro, where there is no supply of citrulline. Comparison between cells deprived of arginine by direct elimination methods or indirectly via arginine degrading enzymes should show differences depending on their ability to handle alternative intermediates (ornithine, citrulline and argininosuccinate) of the urea cycle. The internal state of cells that can, versus those that cannot, use intermediates will metabolically be quite different. These differences should provide clear indicators regarding the sensitivity (susceptibility) of cells to arginine deprivation, from which we will be in a much better position to judge which tumours to treat, and possibly how to design the best treatment to eliminate them.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15886013     DOI: 10.1016/j.semcancer.2005.04.002

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  25 in total

Review 1.  Arginine deprivation, autophagy, apoptosis (AAA) for the treatment of melanoma.

Authors:  N Savaraj; M You; C Wu; M Wangpaichitr; M T Kuo; L G Feun
Journal:  Curr Mol Med       Date:  2010-06       Impact factor: 2.222

2.  Strategies for optimizing the serum persistence of engineered human arginase I for cancer therapy.

Authors:  Everett Stone; Lynne Chantranupong; Candice Gonzalez; Jamye O'Neal; Mridula Rani; Carla VanDenBerg; George Georgiou
Journal:  J Control Release       Date:  2011-10-06       Impact factor: 9.776

3.  Cross-species comparison of metabolite profiles in chemosensory epithelia: an indication of metabolite roles in chemosensory cells.

Authors:  Arie Sitthichai Mobley; Mary T Lucero; William C Michel
Journal:  Anat Rec (Hoboken)       Date:  2008-04       Impact factor: 2.064

4.  IDENTIFYING CANCER SPECIFIC METABOLIC SIGNATURES USING CONSTRAINT-BASED MODELS.

Authors:  A Schultz; S Mehta; C W Hu; F W Hoff; T M Horton; S M Kornblau; A A Qutub
Journal:  Pac Symp Biocomput       Date:  2017

Review 5.  Pegylated arginine deiminase: a novel anticancer enzyme agent.

Authors:  Lynn Feun; Niramol Savaraj
Journal:  Expert Opin Investig Drugs       Date:  2006-07       Impact factor: 6.206

6.  Proteomic and Metabolomic Characterization of a Mammalian Cellular Transition from Quiescence to Proliferation.

Authors:  Ho-Joon Lee; Mark P Jedrychowski; Arunachalam Vinayagam; Ning Wu; Ng Shyh-Chang; Yanhui Hu; Chua Min-Wen; Jodene K Moore; John M Asara; Costas A Lyssiotis; Norbert Perrimon; Steven P Gygi; Lewis C Cantley; Marc W Kirschner
Journal:  Cell Rep       Date:  2017-07-18       Impact factor: 9.423

7.  Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase.

Authors:  Tawnya L Bowles; Randie Kim; Joseph Galante; Colin M Parsons; Subbulakshmi Virudachalam; Hsing-Jien Kung; Richard J Bold
Journal:  Int J Cancer       Date:  2008-10-15       Impact factor: 7.396

Review 8.  Arginine depriving enzymes: applications as emerging therapeutics in cancer treatment.

Authors:  Neha Kumari; Saurabh Bansal
Journal:  Cancer Chemother Pharmacol       Date:  2021-07-26       Impact factor: 3.333

9.  Resistance to arginine deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving c-Myc/HIF-1alpha/Sp4.

Authors:  Wen-Bin Tsai; Isamu Aiba; Soo-yong Lee; Lynn Feun; Niramol Savaraj; Macus Tien Kuo
Journal:  Mol Cancer Ther       Date:  2009-12       Impact factor: 6.261

Review 10.  Arginine deprivation as a targeted therapy for cancer.

Authors:  L Feun; M You; C J Wu; M T Kuo; M Wangpaichitr; S Spector; N Savaraj
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.